News Daily News Reduction in BP Drives Treatment Preference for Hypertensive Patients Michael O'Riordan December 20, 2022
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2022 EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD Todd Neale November 06, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE Todd Neale November 05, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Daily News SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes Michael O'Riordan October 18, 2022
News Conference News TCT 2022 Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus Yael L. Maxwell September 16, 2022
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Daily News Enoxaparin Tops Aspirin for Preventing VTE After Hip or Knee Arthroplasty Todd Neale August 25, 2022
News Daily News New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill Shelley Wood August 23, 2022
News Daily News After COVID-19, Unvaccinated at Risk for Long-term CVD Complications Michael O'Riordan August 16, 2022
News Daily News CV Risk Factor Control Cuts Post-op Nursing Home Transfer for Black Americans Yael L. Maxwell July 22, 2022
News Daily News Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy Todd Neale July 20, 2022